Stocks · News reference
iECURE Says Updated OTC-HOPE Low-Dose Data Showed 74% Reduction In Annualized Hyperammonemic Crises, 57% Reduction In Hyperammonemic Events; Completes Phase 1/2 Dosing Across All Three Cohorts
iECURE, a private clinical-stage genome editing company, reported preliminary safety observations from all nine participants dosed with ECUR-506 across the low-, intermediate- and high-dose cohorts, saying the therapy
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 12:07 PM
- Checked
- Aug 27, 2026, 12:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — PRECISION BIOSCIENCES INC (DTIL)
Filed: 2026-08-24 AccNo: 0001628280-26-058512 Size: 177 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgariECURE Announces Updated Safety And Metabolic Control Data From Phase 1/2 Trial Of ECUR-506 In Neonatal-Onset OTC Deficiency To Be Presented August 27 At SSIEM Symposium
iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.
Read original at benzinga